Main Uses and Indications

Alecast is a leukotriene receptor antagonist primarily prescribed for the long-term management and prevention of symptoms associated with respiratory conditions. Its active mechanism targets specific inflammatory pathways that contribute to airway constriction and mucus production.

Asthma Management

Alecast is used as a maintenance treatment for asthma in adults and pediatric patients. It helps prevent day-to-day symptoms and is effective in managing several specific types of asthma responses:

• Chronic Asthma Prophylaxis: Regular use helps reduce the frequency and severity of asthma attacks by keeping the airways less reactive to triggers.
• Exercise-Induced Bronchoconstriction: It is used to prevent the narrowing of airways that occurs during or after physical exertion.

Allergic Rhinitis

Alecast is indicated for the relief of symptoms associated with allergic rhinitis, where the body overreacts to environmental allergens. It is used for both seasonal and year-round (perennial) allergies:

• Seasonal Allergic Rhinitis: Managing symptoms like sneezing, runny nose, and itchy eyes caused by outdoor allergens such as pollen.
• Perennial Allergic Rhinitis: Controlling chronic symptoms caused by indoor allergens, including dust mites, animal dander, and mold.

Benefits and Clinical Effects

The primary benefit of Alecast is its ability to block leukotrienes, which are chemicals the body releases when breathing in an allergen. By inhibiting these substances, the medication provides several clinical advantages:

• Improved Airflow: By reducing swelling in the lining of the airways and promoting bronchodilation, it makes breathing easier for patients with chronic respiratory inflammation.
• Symptom Reduction: It helps decrease the typical discomforts of allergies, such as nasal congestion and persistent sneezing.
• Nighttime Relief: In asthma patients, it can help reduce nocturnal symptoms, potentially leading to better sleep quality by preventing nighttime coughing or wheezing.
• Non-Steroidal Option: As a leukotriene modifier, it offers a different therapeutic pathway for patients who may require supplemental control alongside other maintenance therapies.

Official Eligibility Profile

The eligibility criteria for Alecast (Alectinib) are strictly defined by regulatory documents, focusing on patient status, age, organ function, and history of severe reactions.

Classification	Eligibility Statement (Regulatory Basis)
Populations Allowed	Adult patients with ALK-positive status confirmed by an approved diagnostic test.
Absolute Exclusion	Patients with a known severe hypersensitivity to the drug or its components.
Age-Related Rule	Safety and effectiveness have not been established in the pediatric population (under 18 years).
Conditional Use	Patients with severe hepatic impairment (Child-Pugh C) are eligible only with a specified, mandatory starting dose reduction.
Reproductive Status	Use is prohibited during pregnancy and breastfeeding. Females of reproductive potential must use effective contraception during treatment and for a specified period (e.g., 5 weeks) after the final dose.
Permanent Discontinuation	The drug must be permanently discontinued if the patient develops specific severe toxicities, such as any grade drug-related Interstitial Lung Disease (ILD)/Pneumonitis or specific elevations in liver enzymes and bilirubin.

---

The structure of official regulatory information defines that only adults who meet the confirmed ALK-positive genetic criteria may use this medicine. Eligibility is constrained by reproductive status and necessitates dose modification for severe liver impairment. Use is permanently discontinued if certain severe organ toxicities are observed during the course of treatment.

Alecast (montelukast) can be affected by, or have minimal effects on, a range of other medicines, mainly due to its primary metabolism through the cytochrome P450 (CYP) enzymes, specifically CYP2C8, CYP2C9, and CYP3A4.

Documented Pharmacokinetic Interactions

Interacting Product Category	Effect on Alecast Exposure	Example Medicines
CYP Enzyme Inducers	Decreases systemic exposure (AUC)	Phenytoin, Phenobarbital, Rifampicin
CYP2C8/2C9 Inhibitors	Increases systemic exposure (e.g., 4.4-fold)	Gemfibrozil

Co-administration of Alecast with strong enzyme inducers like Rifampicin can decrease its blood levels, which may reduce effectiveness, and caution is advised, particularly in children. Conversely, medicines that inhibit its metabolism, such as the cholesterol-lowering drug Gemfibrozil, significantly increase Alecast exposure, though routine dose adjustment is not typically required.

Products with No Clinically Significant Interaction

Alecast is not anticipated to cause clinically important changes in the pharmacokinetics of several common medications, including Theophylline, Warfarin, Digoxin, Prednisone, Prednisolone, or oral contraceptives containing ethinyl estradiol and norethindrone.

Procedural and Condition-Related Constraints

Patients with known aspirin-sensitive asthma should continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while taking Alecast, as this treatment does not change the underlying sensitivity. Alecast should also not be used concurrently with other products that contain the same active ingredient (montelukast).

Alecast functions as a selective antagonist of the cysteinyl leukotriene type 1 (CysLT1) receptor. This receptor is primarily situated on cells within the respiratory tract, including airway smooth muscle cells, airway macrophages, and various pro-inflammatory cell types like eosinophils.

The endogenous ligands for this receptor are the cysteinyl leukotrienes (LTC4, LTD4, and LTE4), eicosanoids derived from arachidonic acid metabolism. Alecast binds to the CysLT1 receptor with high affinity, competitively blocking the binding of LTD4, the most potent CysLT.

This antagonistic interaction inhibits the intracellular signaling cascade typically initiated by CysLT binding, which involves G-protein coupling and subsequent phospholipase C activation. Downstream consequences of CysLT1 blockade include the modulation of calcium mobilization and phosphoinositide hydrolysis. System-level physiological effects in the airways and nasal mucosa involve the inhibition of smooth muscle contraction, the reduction of vascular permeability, and the decrease of cellular recruitment and infiltration.

Alecast is administered only via the oral route, with the dosage and formulation determined by the patient's age and clinical usage pattern. The medicine is available as 10 mg film-coated tablets, 5 mg and 4 mg chewable tablets, and 4 mg oral granules, each corresponding to specific age groups.

Official Dosing and Timing

The standard dosage is once daily, and the treatment is intended for long-term, continuous maintenance. For chronic conditions like asthma and perennial allergic rhinitis, the dose is typically taken in the evening. The 10 mg film-coated tablet may be taken with or without food. Patients receiving treatment for both asthma and allergic rhinitis must take only one single dose daily in the evening.

Age Group	Standard Daily Dose	Form
≥ 15 years	10 mg	Film-Coated Tablet
6 to 14 years	5 mg	Chewable Tablet
6 months to 5 years	4 mg	Chewable Tablet or Granules

Administration Specifics

For the prevention of exercise-induced bronchoconstriction (EIB), a single dose must be administered at least two hours prior to exercise, and an additional dose must not be taken within 24 hours of a standard dose. Special population groups, including older adults, and those with mild-to-moderate renal or hepatic impairment, generally do not require a dosage adjustment. The oral granules must be administered within 15 minutes of opening the sachet. They can be placed directly on the tongue or mixed with a spoonful of approved soft foods (e.g., applesauce, rice) or limited liquids. Once mixed, the preparation must not be stored for later use.

Research Evidence / Overview of Studies for Alecast

This overview summarizes the official research framework for Alecast (montelukast), describing the types of studies conducted and the outcomes they explored, without offering clinical advice or personal predictions. Findings presented here describe group patterns observed in research, not guaranteed individual outcomes.

---

Evidence for Use in Chronic Asthma Management

The evidence for the use of Alecast was studied for its role in long-term study contexts for persistent asthma. The research is largely based on extensive Randomized Controlled Trials (RCTs) and meta-analyses. These studies focused on patients with conditions characterized by fluctuating or episodic manifestations, typically mild to moderate persistent asthma. Research examined outcomes related to systemic or functional imbalance, such as changes in lung function markers, and tracking outcomes related to supplemental rescue medication use. Studies monitored outcomes and reported that groups receiving the medicine showed patterns of change in measured lung function and reported rates of asthma exacerbations relative to the control groups over the observation period.

---

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Alecast was studied for use in conditions involving periods of heightened symptoms related to seasonal and perennial allergic rhinitis. Research explored its effect across a wide age range. Studies conducted during periods of increased symptom activity reported patterns of change in measured symptom scores and quality of life metrics compared to placebo groups. Comparative evidence shows that the findings were mixed when Alecast was directly compared to the effects of nasal corticosteroids, and these comparisons were used in research to help contextualize the observed symptom changes.

---

Evidence for Prevention of Exercise-Induced Bronchoconstriction (EIB)

Research has explored the use of Alecast for conditions associated with acute or disruptive episodes, specifically breathing difficulties triggered by physical exertion (EIB). Studies were conducted in adults and children with a history of EIB, often using a controlled exercise challenge. Studies observed that the pattern against the fall in FEV1 was measured following the challenge, and research explored whether this pattern was still observed up to 24 hours after dosing.

---

Areas of Research Uncertainty and Study Gaps

The existing research highlights what is known — and what is still uncertain. One key area of research uncertainty is the heterogeneity of individual response. The study results reflect the specific conditions under which they were conducted, and research does not predict whether an individual will experience a similar pattern of change. Additionally, comparative evidence is lacking in some areas, and long-term effects are not fully established for certain rare or delayed outcomes. Research is ongoing to provide more insight into all aspects of its use.

Common questions about Alecast (FAQ)

Q: How is Alecast chemically different from a standard over-the-counter antihistamine?

A: The drug belongs to the Leukotriene Receptor Antagonist (LTRA) pharmacological class. Regulatory information confirms the mechanism of action involves blocking leukotrienes, which are inflammatory chemicals in the body, rather than targeting histamine receptors like many common antihistamines.

Q: What information is available about the use of Alecast in the elderly population?

A: According to official prescribing information, specific dosage adjustment is not generally required for older adults. The regulatory label states that the use of the medicine remains guided by its approved indications.

Q: Does Alecast cause drowsiness that could affect the ability to drive or operate machinery?

A: The official safety profile highlights that neuropsychiatric events may occur, which include effects like sleep disturbances or issues with attention. Because of this potential, individuals are cautioned that their ability to drive or safely operate machinery could be impacted.

Q: What are the possible implications of Alecast for people with existing liver problems?

A: Regulatory documentation specifies that no dosage change is usually required for patients with mild-to-moderate liver (hepatic) impairment. For cases of severe impairment, official guidance outlines that a dose adjustment is necessary.

Q: Does Alecast interact with any common over-the-counter pain relievers like aspirin or ibuprofen?

A: Regulatory documents do not indicate a general pharmacokinetic interaction between Alecast and most over-the-counter pain relievers. However, official guidance notes that individuals with known aspirin-sensitive asthma should continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while the medicine is being used.

Q: How should a patient approach taking Alecast if they also need a cold or flu medication?

A: Official regulatory documents indicate that Alecast is not expected to cause clinically significant changes when taken with several common prescription medications. Because cold and flu remedies can contain various active ingredients, full disclosure of all concurrent products to a healthcare provider is noted as important.

Q: Why is Alecast often prescribed as an add-on therapy to other existing treatments?

A: Official research overviews indicate that Alecast is commonly prescribed as a complementary therapy alongside other existing treatments. Regulatory summaries suggest this pattern of use is typically observed in adults whose symptoms are not adequately controlled by existing inhaled corticosteroids alone.

Q: Does the manufacturer define any specific warnings for people with allergies to the drug's inactive ingredients?

A: Official safety information includes a specific warning about inactive ingredients for certain patient groups. Specifically, the chewable tablet formulation contains aspartame, which is a source of phenylalanine. This content is noted as a safety consideration for patients with phenylketonuria (PKU).

Q: Why is the official drug name sometimes referenced with 'sodium' attached (Alecast sodium)?

A: The official active ingredient is referred to as montelukast sodium. The addition of 'sodium' refers to the salt form of the active chemical compound, which is used in the preparation of the final medicine.

Q: How long does it typically take for the first noticeable effects of Alecast to begin?

A: Studies on the medicine's pharmacokinetics show that Alecast is rapidly absorbed after oral intake. The point of peak concentration in the blood (Cmax) is generally reached within two to four hours, depending on the specific formulation taken.

Q: How long does a single dose of Alecast generally remain active in the body?

A: Official data describing how the medicine is processed in the body shows that the mean plasma half-life of the active ingredient typically ranges from 2.7 to 5.5 hours. The half-life is the time it takes for the concentration of the medicine in the blood to decrease by half.

Q: What should a patient know if a dose of Alecast is unintentionally missed?

A: Official regulatory instructions for a missed dose advise against taking two doses together. The standard guidance is to skip the missed dose and resume taking the medicine at the regularly scheduled time.

Q: Is weight gain a frequently reported side effect associated with Alecast use?

A: Regulatory safety documents do not list weight gain among the very common, common, or rare adverse reactions reported for this medicine. Adverse reactions are formally documented based on the frequency observed in clinical studies and post-marketing surveillance.

Q: What information exists regarding Alecast's potential effect on a person's mood or behavior?

A: Official labeling carries a prominent Boxed Warning for the potential risk of serious neuropsychiatric events. These reported events can include changes in mood and behavior such as agitation, aggression, depression, and suicidal thoughts.

Q: Have there been reports of changes in sleep patterns or vivid/abnormal dreams while taking Alecast?

A: The official safety profile includes reports of changes to sleep patterns. These reported effects include sleep disturbances such as insomnia, somnambulism (sleepwalking), and dream anomalies, which may include vivid or disturbing nightmares.

Q: Are there any documented long-term safety concerns or late-onset side effects of Alecast?

A: The official safety profile notes that neuropsychiatric symptoms have been reported both while taking the medicine and after discontinuing its use. Furthermore, regulatory documents indicate that long-term effects are not fully established for all rare or delayed outcomes.

Q: How often do people report feeling tiredness or fatigue while on this medication?

A: Fatigue (tiredness) is an effect that is officially listed among the adverse effects reported in the safety information for Alecast. This information is based on the frequency observed in clinical studies.

Q: Can Alecast cause common gastrointestinal side effects like nausea or diarrhea?

A: The official regulatory safety profile lists several potential gastrointestinal effects. Abdominal pain is a common side effect, and instances of nausea and diarrhea have also been reported.

Q: Is an increase in muscle aches or pain a known side effect of Alecast?

A: The official safety profile includes reports of musculoskeletal effects. These documented adverse events include reports of myalgia (muscle aches or pain) and arthralgia (joint pain).

Q: Are there concerns about Alecast causing dry mouth or throat irritation?

A: Regulatory safety information does not commonly list dry mouth as a reported adverse event. However, upper respiratory effects like pharyngitis (sore throat) are noted as a common side effect.

Q: Is a slight skin rash considered a common adverse event of Alecast?

A: The safety profile reports instances of skin rash and other dermatologic manifestations, including urticaria (hives). These are documented based on the adverse events reported during clinical development and post-marketing surveillance.

Q: Does having pre-existing kidney disease affect a person's eligibility to use Alecast?

A: Regulatory documentation indicates that Alecast is minimally eliminated by the kidneys. Therefore, official prescribing information states that no specific dosage adjustment is required for patients with renal insufficiency (kidney disease).

Q: Is there an interaction or safety warning regarding the consumption of alcohol while taking Alecast?

A: Official prescribing information does not list a direct interaction between Alecast and alcohol. However, official guidance notes that because the medicine is processed by the liver, concurrent alcohol consumption may potentially increase the risk of liver-related side effects.

Q: Are there any specific foods or nutritional supplements that should be avoided while using Alecast?

A: Official regulatory documents do not specify any particular foods that must be strictly avoided while taking Alecast. General official guidance emphasizes the importance of informing a healthcare provider of all supplements and herbal remedies being used.

Q: Is Alecast a type of drug that requires regular lab monitoring (like blood tests) to check for safety?

A: Official documentation indicates that the drug is permanently discontinued if specific, severe elevations in liver enzymes are observed. However, routine lab tests are not typically mandated solely to check for safety based on renal function.

Q: In clinical trials, how did the effectiveness of Alecast compare to a placebo?

A: Clinical research for its approved uses consistently involved randomized controlled trials where patient outcomes were tracked against placebo groups. This research framework was used to measure patterns of change in markers like lung function and patient-reported symptom scores for the approved uses.

Q: Is Alecast approved for use in all types of its target condition, or only specific subtypes?

A: The medicine is officially indicated for the prophylaxis and chronic treatment of asthma, and for the relief of symptoms of seasonal and perennial allergic rhinitis. Official warnings clearly state that Alecast is not indicated for use during acute asthma attacks.

Q: Is there any information on how Alecast might affect someone with a history of anxiety disorders?

A: The official safety profile reports that Alecast is associated with neuropsychiatric events, including feelings of anxiousness and anxiety. Regulatory documents note that for individuals with a history of psychiatric disorders, the risks should be carefully considered before the medicine is prescribed.

Storage and Disposal Requirements

Alecast must be stored according to official regulatory specifications to maintain product stability and effectiveness.

Detail	Regulatory Requirement
Temperature Range	Store at mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F), consistent with controlled room temperature.
Environmental Protection	The product must be protected from moisture and light and kept in the container it came in.
Child Safety	Keep Alecast and all medicines out of reach of children.
Handling Oral Granules	Oral granules must be administered within 15 minutes of opening the packet; do not store any mixed portion for later use.
Disposal	Unused or expired Alecast must be disposed of in accordance with local regulatory requirements. Do not dispose of the medicine via household wastewater.

Storage is strictly mandated to be within the specified temperature range and requires stringent protection from environmental factors, especially light and moisture. The official instructions require adherence to local pharmaceutical waste disposal rules for unused or expired product.